Table 1.

Patient characteristics, including detection (yes or no) of cord blood-origin maternal microchimerism (CB-MMc) post-CB transplantation (CBT), degree of HLA matching of CB units to patient and of unit to unit (in double CBT), CB-NIMA target used to detect CB-MMc (n/a = not available or not informative), sustained win-lose (W-L) engraftment status of a double CBT, day of engraftment defined as the first of 3 consecutive days of an absolute neutrophil count of ≥ 0.5×10⁹/L, acute and chronic GVHD, relapse, last contact and death status, as well as pre-transplant minimal residual disease (MRD) assessed by standard multiparameter flow cytometry, cytogenetic and molecular assay below morphologically identifiable disease. Blank entries indicate data not applicable (e.g. a relapse event did not occur in that patient).

Patient No.	CB-MMc+ (day 30 to ~400)	Sex	Disease	Age diag (yr.)	Age transp (yr.)	HLA match units to patient	HLA match unit to unit	CB-NIMA targeted by qPCR	Unit engr	Engr day	MRD+	day pre-CBT of MRD test	aGVHD (day 0 to~80)	cGVHD (day 80 to ~365)	Relapse at day	Alive at day	Death at day
007	y	f	AML	60.4	61.0	5/6 & 5/6	6/6	DRB1*07 & DRB1*04	W-L	16	n	35	II	0			156a
017	y	f	AML	51.8	53.7	4/6 & 4/6	3/6	B*13 & DRB1*15	W-L	20	n	24	II	0		1916
025	y	f	ALL	36.2	40.7	4/6 & 4/6	5/6	DRB1*15 & DRB1*04	W-L	17	n	27	II	mild		1524
085	y	f	AML	28.7	31.0	4/6 & 4/6	2/6	n/a & DQB1*06	W-L	28	n	25	III	moderate		1240
125	y	m	AML	60.4	60.9	4/6 & 4/6	3/6	DRB1*15 & A*30	W-L	28	n	32	0	unk.		917
048	y	m	ALL	34.5	35.2	5/6	single	DRB1*04		21	n	14	II	mild		1605
108	y	m	ALL	4.1	4.6	5/6	single	DRB1*01		30	n	29	II	moderate		865
011	n	f	ALL	2.3	5.4	5/6 & 5/6	5/6	DRB1*03 & n/a	W-L	15	n	29	II	mild		3360
014	n	f	AML	32.3	38.7	6/6 & 5/6	5/6	DQB1*03 & DRB1*04	W-L	31	n	26	II	mild			1396b
015	n	m	ALL	32.3	32.7	5/6 & 4/6	4/6	n/a & DRB1*07	W-L	13	y	33	II	0		1218
021	n	m	TCL	43.2	44.2	4/6 & 4/6	3/6	n/a & B*44	W-L	31	n	21	II	0		1595
029	n	f	ALL	36.4	38.9	4/6 & 4/6	4/6	DRB1*10 & n/a	mixed	23	n	22	0	0			495a,c
032	n	m	ALL	44.7	45.4	6/6 & 4/6	4/6	n/a & DRB1*16	W-L	15	n	18	II	mild		1612
033	n	m	ALL	19.4	19.9	4/6 & 4/6	4/6	A*30 & A*30	W-L	26	y	35	0	0			135a
034	n	f	AML	67.9	68.5	4/6 & 4/6	3/6	n/a & DRB1*03	W-L	24	y	34	II	0	208		242d
040	n	f	ALL	14.2	30.6	5/6 & 5/6	5/6	n/a & DRB1*01	W-L	21	n	34	II	mild		1776
053	n	m	ALL	58.0	58.6	4/6 & 4/6	2/6	DRB1*04 & n/a	W-L	16	n	30	II	0			1077h
063	n	m	AML	63.9	64.3	4/6 & 4/6	3/6	DRB1*01 & n/a	W-L	16	y	24	II	unk.	26		61h
066	n	f	GATA2	44.6	45.0	4/6 & 4/6	4/6	DRB1*03 & DRB1*03	W-L	23	n	32	III	0			424e
068	n	m	CML	55.4	58.3	4/6 & 4/6	3/6	DRB1*07 & n/a	W-L	19	y	42	II	0		1473
072	n	f	AML	16.6	17.0	4/6 & 4/6	3/6	DRB1*13 & DRB1*15	W-L	15	n	28	III	0	760	1309
087	n	f	ALL	30.3	30.8	4/6 & 4/6	2/6	DRB1*08 & n/a	W-L	16	n	28	II	0		1075
088	n	m	MDS	23.2	23.5	5/6 & 4/6	5/6	DRB1*15 & DQB1*06	mixed	15	y	26	III	severe			151f
093	n	m	AML	38.8	39.9	5/6 & 6/6	5/6	DRB1*08 & n/a	W-L	9	n	36	I	mild	480		494c
095	n	f	ALL	33.3	33.8	4/6 & 4/6	2/6	n/a & DRB1*08	W-L	17	n	25	II	mild	458	1100
096	n	f	ALL	20.7	27.0	4/6 & 4/6	2/6	DRB1*07 & DRB1*07	W-L	22	n	27	II	mild		1214
107	n	m	ALL	45.5	46.8	4/6 & 4/6	4/6	n/a & DRB1*13	W-L	23	y	36	III	moderate			195g
113	n	f	MDS	33.3	34.5	6/6 & 4/6	4/6	DRB1*07 & n/a	W-L	15	n	27	0	0	1036	1040
120	n	m	ALL	33.5	34.9	5/6 & 6/6	5/6	A*30 & n/a	W-L	20	y	26	0	0	279		358d
124	n	m	AML	49.9	50.4	5/6 & 4/6	5/6	n/a & DRB1*15	W-L	19	n	34	0	unk.		769
129	n	f	AML	27.7	28.1	4/6 & 4/6	4/6	DRB1*15 & n/a	W-L	18	n	21	II	0		857
018	n	m	ALL	1.5	1.9	5/6	single	DRB1*07		29	n	42	II	moderate		1846
073	n	m	ALL	14.0	14.5	4/6	single	DRB1*01		16	n	26	II	0		1114
098	n	f	AML	7.7	10.5	4/6	single	DRB1*15		16	n	29	II	0		1228
112	n	m	AML	35.0	35.5	4/6	single	DRB1*07		19	y	21	II	mild		872
122	n	f	AML & ALL	0.6	2.2	5/6	single	DRB1*03		12	n	25	II	0		861

Cause of death:

^(a)pneumonia/acute respiratory failure

^(b)metastatic squamous cell carcinoma

^(c)sepsis/shock

^(d)relapse-related

^(e)multiple organ dysfunction syndrome

^(f)status epilepticus/acute renal failure/thrombotic microangiopathy

^(g)acute hemorrhagic stroke

^(h)unknown.